Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) Director Suvretta Capital Management, L acquired 42,000 shares of the business's stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $9.60 per share, with a total value of $403,200.00. Following the acquisition, the director now directly owns 7,957,365 shares of the company's stock, valued at $76,390,704. This represents a 0.53 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Benitec Biopharma Stock Performance
BNTC opened at $9.78 on Friday. Benitec Biopharma Inc. has a twelve month low of $2.69 and a twelve month high of $12.89. The firm's 50-day moving average price is $10.28 and its 200 day moving average price is $9.16.
Analyst Ratings Changes
Several brokerages have recently issued reports on BNTC. Oppenheimer began coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They issued an "outperform" rating and a $35.00 target price on the stock. Piper Sandler reiterated an "overweight" rating on shares of Benitec Biopharma in a research report on Friday, October 18th. JMP Securities lifted their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a "market outperform" rating in a research report on Monday, October 14th. Finally, Guggenheim reiterated a "buy" rating and issued a $17.00 target price on shares of Benitec Biopharma in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $22.60.
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
Discover the coin set to explode before 2025!
Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
Check Out Our Latest Report on Benitec Biopharma
Hedge Funds Weigh In On Benitec Biopharma
A number of institutional investors and hedge funds have recently bought and sold shares of BNTC. GAMMA Investing LLC boosted its position in Benitec Biopharma by 53.0% during the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 1,884 shares during the last quarter. Acuta Capital Partners LLC acquired a new position in Benitec Biopharma during the third quarter worth about $274,000. Simplify Asset Management Inc. acquired a new position in Benitec Biopharma during the second quarter worth about $358,000. Geode Capital Management LLC boosted its position in Benitec Biopharma by 31.3% during the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company's stock worth $772,000 after acquiring an additional 20,012 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Benitec Biopharma by 35.5% during the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock worth $1,266,000 after acquiring an additional 64,092 shares during the last quarter. 52.19% of the stock is currently owned by institutional investors and hedge funds.
About Benitec Biopharma
(
Get Free Report)
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
